glp-1 for mash A New Phase in Therapeutics: Resmetirom (THR-β Agonist) and Semaglutide (GLP-1 Receptor Agonist) Reversing fibrosis in metabolic dysfunction–associated
Description
All are GLP-1 agonists
Important observations All five clinical trials that were included in the analysis reported GLP-1 receptor agonist-mediated reduction in substance use disorder, with two trials respectively reporting a significant therapeutic impact of GLP-1 receptor agonist in reducing alcohol use disorder and nicotine use disorder
R.MohammedI.BsheshK.MareiI.YeK.DingH.et al (2022)
Real Care
Which medication is better for people with diabetes
